193 related articles for article (PubMed ID: 11309704)
1. New advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Hematol; 2001 Apr; 38(2 Suppl 3):15-20. PubMed ID: 11309704
[TBL] [Abstract][Full Text] [Related]
2. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate therapy in multiple myeloma: past, present, future.
Jantunen E
Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
7. Bone disease in myeloma.
Berenson JR
Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
[TBL] [Abstract][Full Text] [Related]
8. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Pozzi S; Raje N
Oncologist; 2011; 16(5):651-62. PubMed ID: 21493759
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in multiple myeloma.
Berenson JR
Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
[TBL] [Abstract][Full Text] [Related]
10. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
12. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
[TBL] [Abstract][Full Text] [Related]
16. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
[TBL] [Abstract][Full Text] [Related]
17. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
18. Myeloma bone disease.
Berenson JR
Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
[TBL] [Abstract][Full Text] [Related]
19. Bone complications in multiple myeloma.
Berenson JR; Rajdev L; Broder M
Cancer Biol Ther; 2006 Sep; 5(9):1082-5. PubMed ID: 16969119
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
